Lipids & Metabolic

The recent price cuts of the PCSK9 inhibitor alirocumab (Praluent) aren’t enough to make the cholesterol-lowering drug cost-effective compared to ezetimibe, according to an analysis published in the Jan. 1 issue of the Annals of Internal Medicine.

The Mediterranean diet nudged the DASH diet out of the top spot for the best overall diet of 2019 in rankings released Jan. 2 by U.S. News and World Report. Those two approaches shared the No. 1 billing last year.

A new feature for a personal diabetes management application leverages AI to predict the likelihood of a user experiencing a hypoglycemic event in the next one to four hours.

Patients with diabetes and peripheral artery disease (PAD) are significantly more likely than nondiabetics with PAD to die from cardiovascular causes or have a heart attack or stroke, according to a subanalysis of the EUCLID trial.

A Singapore-based research team is cautioning diabetics to be mindful of what apps, if any, they’re using to manage their condition after an analysis found the majority of such aids lack the ability to effectively monitor a patient’s diet, activity, medications, glucose and insulin.

A recent analysis of last year’s FOURIER trial has found evolocumab, a PCSK9 inhibitor developed to treat hyperlipidemia, can robustly reduce low-density lipoprotein cholesterol (LDL-C) in patients without any major concern for individual-level variability in response.

Questioning older patients about their weight earlier in life could be a low-tech, low-cost way to better predict a person’s future risk of heart disease, according to a study published in the Journal of the American Heart Association.

After years of decline, amputations are increasing among diabetic patients in the U.S., Reuters reported.

As insulin prices in the U.S. continue to surge, lower-income diabetics are struggling to afford a drug their life depends on, researchers report in a JAMA Internal Medicine study published Dec. 3.

The U.S. Department of Agriculture rolled out its final rule on school nutrition standards Dec. 6, allowing schools to ease up on whole grains, permanently serve 1 percent flavored milk and take their time reducing sodium levels in school lunches.

Liraglutide was associated with a 10 percent reduction in major cardiovascular events for patients with type 2 diabetes in a real-world population, offering hope that the cardioprotective benefits observed in randomized trials translate to regular clinical practice.

A little weight lifting can have a big impact on heart health, even in the absence of aerobic endurance training, according to recent research in Medicine & Science in Sports & Exercise.